Live Breaking News & Updates on Analyst Recommendations For Rocket Pharmaceuticals|Page 6

Stay updated with breaking news from Analyst recommendations for rocket pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at StockNews.com

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a research note issued to investors on Monday. Other equities analysts also recently issued reports about the company. Canaccord Genuity Group cut their target price on Rocket Pharmaceuticals from $49.00 to $47.00 and set a “buy” rating on the […] ....

Gaurav Shah , Stifel Nicolaus , Needham Company , Analyst Recommendations For Rocket Pharmaceuticals , Insider Transactions At Rocket Pharmaceuticals , Clearstead Advisors , Advisor Group Holdings Inc , Rocket Pharmaceuticals Stock Down , Rocket Pharmaceuticals , News Ratings For Rocket Pharmaceuticals Daily , Rocket Pharmaceuticals Inc , Life Insurance Co , Wells Fargo Company , Steward Partners Investment Advisory , Securities Exchange Commission , Canaccord Genuity Group , Get Free Report , Genuity Group , Chardan Capital , Pharmaceuticals Stock Down , Exchange Commission , Group Holdings , Partners Investment Advisory , Metropolitan Life Insurance , Life Insurance , Rocket Pharmaceuticals Daily ,

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biotechnology company’s stock. Several other equities analysts have also recently commented on the company. Chardan Capital restated a buy rating and set a $61.00 target price on shares […] ....

Gaurav Shah , Stifel Nicolaus , Hightower Advisors , Jpmorgan Chase Co , Metlife Investment Management , Rocket Pharmaceuticals , Rocket Pharmaceuticals Price Performance , Canaccord Genuity Group , News Ratings For Rocket Pharmaceuticals Daily , Synovus Financial Corp , Analyst Recommendations For Rocket Pharmaceuticals , Rocket Pharmaceuticals Inc , Needham Company , Free Report , Moderate Buy , Get Free Report , Tower Advisors , Life Investment Management , Financial Corp , Rocket Pharmaceuticals Daily , Nasdaq Rckt , Initiated Coverage , Stocknews Com ,

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $50.09 Consensus PT from Analysts

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $50.09 Consensus PT from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , Gaurav Shah , Stifel Nicolaus , Insider Activity At Rocket Pharmaceuticals , Analyst Recommendations For Rocket Pharmaceuticals , Rocket Pharmaceuticals Price Performance , Securities Exchange Commission , Needham Company , Nuveen Asset Management , Dana Investment Advisors Inc , Rocket Pharmaceuticals , Rocket Pharmaceuticals Company Profile , News Ratings For Rocket Pharmaceuticals Daily , Intercept Hong Kong Ltd , Canaccord Genuity Group , Wells Fargo Company , Rocket Pharmaceuticals Inc , Get Free Report , Marketbeat Ratings , Genuity Group , Exchange Commission , Asset Management , Investment Advisors , Get Free , Rocket Pharmaceuticals Daily ,

Brokerages Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Target Price at $50.09

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given a consensus recommendation of “Buy” by the twelve analysts that are currently covering the stock, Marketbeat reports. Twelve investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the […] ....

New Zealand General , New Zealand , Stifel Nicolaus , Gaurav Shah , Institutional Investors Weigh In On Rocket Pharmaceuticals , Blackrock Inc , Vanguard Group Inc , Needham Company , Maverick Capital Ltd , Securities Exchange Commission , Wellington Management Group , Rocket Pharmaceuticals , Analyst Recommendations For Rocket Pharmaceuticals , News Ratings For Rocket Pharmaceuticals Daily , Rocket Pharmaceuticals Inc , Rocket Pharmaceuticals Stock , Canaccord Genuity Group , Get Free Report , Genuity Group , Exchange Commission , Management Group , Street Corp , Vanguard Group , Get Free , Rocket Pharmaceuticals Daily , Nasdaq Rckt ,

Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $50.09

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are covering the company, MarketBeat Ratings reports. Twelve investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock […] ....

New Zealand General , New Zealand , Stifel Nicolaus , Needham Company , Rocket Pharmaceuticals Price Performance , Canaccord Genuity Group , Wellington Management Group , Rocket Pharmaceuticals , News Ratings For Rocket Pharmaceuticals Daily , Vanguard Group Inc , Analyst Recommendations For Rocket Pharmaceuticals , Rocket Pharmaceuticals Company Profile , Blackrock Inc , Maverick Capital Ltd , Rocket Pharmaceuticals Inc , Get Free Report , Marketbeat Ratings , Management Group , Street Corp , Vanguard Group , Get Free , Rocket Pharmaceuticals Daily , Nasdaq Rckt ,